Jubilant Ingrevia Ltd (NSE: JUBLINGREA, BSE: 543271) is a Noida, Uttar Pradesh-based company in the Other Specialty Chemicals industry. With a market capitalisation of ₹9,493 Cr, it ranks #580 by market cap among the 6,189 Indian listed companies on FinBizNet, and #1 of 8 in Other Specialty Chemicals. At ₹601.90 (as of 26 Oct 2026), the share price is 24.3% below its 52-week high of ₹795.00 and 12.0% above its 52-week low of ₹537.30. The share price is down 14.8% over one year and down 17.0% over three months.
| Current Price | ₹601.90 |
|---|---|
| Market Cap | ₹9,493 Cr |
| NSE Symbol | JUBLINGREA |
| BSE Code | 543271 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Other Specialty Chemicals |
| P/E Ratio | 34.4 |
| Return on Equity | 9.18% |
| Return on Assets | 4.92% |
| 52-Week Range | ₹537.30 – ₹795.00 |
| 1-Year Price Change | -14.8% |
| 3-Month Price Change | -17.0% |
| Beta (1Y) | 0.37 |
| Dividend Yield | 0.83% |
| Headquarters | Noida, Uttar Pradesh |
| Website | jubilantingrevia.com |
| Revenue | ₹1,300 Cr |
|---|---|
| Net Profit | ₹106 Cr |
| Net Margin | 8.1% |
| EPS (Basic) | ₹6.70 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant LSI
1. Speciality Chemicals-This segment offers pyridine and picolines, fine chemicals, and crop protection chemicals. It also provides custom development and manufacturing services. 2. Nutrition & Health Solutions-This segment offers nutrition and health ingredients, and animal and human nutrition health solutions. 3. Chemical Intermediates-This segment offers acetyls and specialty ethanol. 4. Inter Segment Revenue-0
1. Speciality Chemicals-50.5% 2. Nutrition & Health Solutions-18% 4. Chemical Intermediates-38%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Jubilant Ingrevia Ltd | ₹9,493 Cr | 34.4 | 9.18% | ₹1,300 Cr | -14.8% |
| Chemplast Sanmar Ltd | ₹2,896 Cr | -10.3 | -14.64% | ₹1,125 Cr | -53.5% |
| Shree Pushkar Chemicals & Fertil | ₹1,520 Cr | 21.8 | 12.20% | ₹280 Cr | +13.2% |
| Biopol Chemicals Limited | ₹45 Cr | 3.9 | — | — | — |
| Roopa Industries Ltd. | ₹34 Cr | 413.8 | 0.47% | — | -21.3% |
| Gujarat Petrosynthese Ltd. | ₹27 Cr | 11.6 | 4.62% | ₹7 Cr | -27.2% |
| Asian Petroproducts & Exports Ltd. | ₹23 Cr | 18.9 | 9.79% | — | +9.1% |
| Vikas Wsp Ltd. | ₹17 Cr | -0.3 | -3.33% | — | -35.4% |
Listed by market capitalisation. Ratios are shown for context only.
Jubilant Ingrevia Ltd is trading at ₹601.90, with a market capitalisation of ₹9,493 Cr.
Jubilant Ingrevia Ltd operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Other Specialty Chemicals).
Jubilant Ingrevia Ltd has a P/E of 34.4 and a return on equity of 9.18%.
Jubilant Ingrevia Ltd is listed on the NSE under the symbol JUBLINGREA and on the BSE under the scrip code 543271.
Jubilant Ingrevia Ltd's share price is down 14.8% over one year and down 17.0% over three months. Its 52-week range is ₹537.30 to ₹795.00.
In Q1 FY27, Jubilant Ingrevia Ltd reported revenue of ₹1,300 Cr and net profit of ₹106 Cr, with basic EPS of ₹6.7 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.